INmune Bio, Inc. (NASDAQ:INMB) Given Consensus Rating of “Hold” by Analysts

Shares of INmune Bio, Inc. (NASDAQ:INMB) have earned an average rating of “Hold” from the seven ratings firms that are covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $18.00.

INMB has been the subject of several recent research reports. Wall Street Zen upgraded INmune Bio from a “sell” rating to a “hold” rating in a research note on Sunday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of INmune Bio in a report on Wednesday, October 8th.

Institutional Trading of INmune Bio

Institutional investors and hedge funds have recently made changes to their positions in the company. Cambridge Investment Research Advisors Inc. acquired a new stake in shares of INmune Bio in the 1st quarter valued at approximately $180,000. Bank of New York Mellon Corp lifted its stake in shares of INmune Bio by 9.0% in the first quarter. Bank of New York Mellon Corp now owns 54,923 shares of the company’s stock worth $429,000 after acquiring an additional 4,521 shares during the period. Pekin Hardy Strauss Inc. boosted its holdings in INmune Bio by 13.1% in the first quarter. Pekin Hardy Strauss Inc. now owns 94,300 shares of the company’s stock valued at $736,000 after acquiring an additional 10,950 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in INmune Bio by 19.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 41,320 shares of the company’s stock valued at $323,000 after acquiring an additional 6,654 shares during the last quarter. Finally, Nuveen LLC acquired a new stake in INmune Bio during the 1st quarter valued at approximately $129,000. Institutional investors own 12.72% of the company’s stock.

INmune Bio Stock Performance

NASDAQ:INMB opened at $1.63 on Monday. INmune Bio has a 52 week low of $1.53 and a 52 week high of $11.64. The firm’s 50-day simple moving average is $1.91 and its 200 day simple moving average is $3.90. The firm has a market cap of $43.33 million, a price-to-earnings ratio of -0.77 and a beta of 0.95.

INmune Bio (NASDAQ:INMB) last announced its earnings results on Thursday, October 30th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.07. Sell-side analysts anticipate that INmune Bio will post -2.24 EPS for the current year.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.